Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

被引：0
|
作者：
Avasarala, Jagannadha [1 ]
机构：
[1] Univ Kentucky Med Ctr, Dept Neurol, 740 S Limestone, Lexington, KY 40536 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷 / 12期
关键词：
Anti-CD20; drugs; B cell repopulation; CD19 cell counts; COVID; 19; susceptibility; dosing frequency; multiple sclerosis; vaccine response; DEPLETION;
D O I：
10.1111/bcp.16248
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：3094 / 3096
页数：3
相关论文
共 50 条
  • [21] Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
    Januel, Edouard
    De Seze, Jerome
    Vermersch, Patrick
    Maillart, Elisabeth
    Bourre, Bertrand
    Pique, Julie
    Moisset, Xavier
    Bensa, Caroline
    Maarouf, Adil
    Pelletier, Jean
    Vukusic, Sandra
    Audoin, Bertrand
    Louapre, Celine
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (07) : 1155 - 1159
  • [22] Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
    Louapre, Celine
    Ibrahim, Michella
    Maillart, Elisabeth
    Abdi, Basma
    Papeix, Caroline
    Stankoff, Bruno
    Dubessy, Anne-Laure
    Bensa-Koscher, Caroline
    Creange, Alain
    Chamekh, Zina
    Lubetzki, Catherine
    Marcelin, Anne-Genevieve
    Corvol, Jean-Christophe
    Pourcher, Valerie
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (01) : 24 - 31
  • [23] Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients
    Torgauten, Hilde M.
    Onyango, Therese Bredholt
    Ljostveit, Sonja
    Hallin, Erik I.
    Serkland, Trond T.
    Skrede, Silje
    Langeland, Nina
    Cox, Rebecca Jane
    Wergeland, Stig
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [24] Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
    Alvarez, Enrique
    Longbrake, Erin E.
    Rammohan, Kottil W.
    Stankiewicz, James
    Hersh, Carrie M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [25] The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVID-19 in Multiple Sclerosis
    Sen, Sedat
    Arslan, Gokhan
    Tutuncu, Melih
    Demir, Serkan
    Dinc, Oyku
    Gunduz, Tuncay
    Uzunkopru, Cihat
    Gumus, Haluk
    Tutuncu, Mesude
    Akcin, Ruveyda
    Ozakbas, Serkan
    Koseoglu, Mesrure
    Bunul, Sena Destan
    Gezer, Ozan
    Cetinkaya Tezer, Damla
    Baba, Cavid
    Acar Ozen, Pinar
    Koc, Rabia
    Elverdi, Tugrul
    Uygunoglu, Ugur
    Kurtuncu, Murat
    Beckmann, Yesim
    Gungor Dogan, Ipek
    Turan, Omer Faruk
    Boz, Cavit
    Terzi, Murat
    Tuncer, Asli
    Saip, Sabahattin
    Karabudak, Rana
    Kocazeybek, Bekir
    Efendi, Husnu
    Bilge, Ugur
    Siva, Aksel
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2023, 60 (03): : 252 - 256
  • [26] COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
    Zabalza, Ana
    Cardenas-Robledo, Simon
    Tagliani, Paula
    Arrambide, Georgina
    Otero-Romero, Susana
    Carbonell-Mirabent, Pere
    Rodriguez-Barranco, Marta
    Rodriguez-Acevedo, Breogan
    Restrepo Vera, Juan Luis
    Resina-Salles, Mireia
    Midaglia, Luciana
    Vidal-Jordana, Angela
    Rio, Jordi
    Galan, Ingrid
    Castillo, Joaquin
    Cobo-Calvo, Alvaro
    Comabella, Manuel
    Nos, Carlos
    Sastre-Garriga, Jaume
    Tintore, Mar
    Montalban, Xavier
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (10) : 3384 - 3395
  • [27] Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies
    Conway, Sarah
    Gupta, Saumya
    Healy, Brian
    Chuang, Tzu-Ying
    Stazzone, Lynn
    Sullivan, John
    Polgar-Turcsanyi, Mariann
    Chitnis, Tanuja
    Houtchens, Maria
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 87
  • [28] The Impact of Disease-Modifying Therapies of Multiple Sclerosis on the Effectiveness of the BBIBP-CorV COVID-19 Vaccine
    Ghaffari, Mehran
    Moghadam, Nahid Beladi
    Paybast, Sepideh
    Aghamiri, Seyed Hossein
    Haghighi, Mehrdad
    Javadi, Abdolreza
    Rafatpanah, Houshang
    Le, Saba Sadeghi Rashed
    Nahayati, Mohammad Ali
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2024, 19 (06):
  • [29] Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
    Etemadifar, Masoud
    Sami, Ramin
    Salari, Mehri
    Sedaghat, Nahad
    Sigari, Amirhossein Akhavan
    Aghababaei, Ali
    Najafi, Mohammadreza
    Tehrani, Donya Sheibani
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [30] COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
    Baker, D.
    Roberts, C. A. K.
    Pryce, G.
    Kang, A. S.
    Marta, M.
    Reyes, S.
    Schmierer, K.
    Giovannoni, G.
    Amor, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 202 (02) : 149 - 161
12345